Estela Rodriguez and Zosia Piotrowska
Nov 24, 2024, 18:32
Estela Rodriguez: A great overview of treatment paradigm for EGFR20ins NSCLC by Zosia Piotrowska
Estela Rodriguez, Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, posted on X:
“Zosia Piotrowska, Mass General Cancer Center gives a great overview of treatment paradigm for EGFR20ins NSCLC and future directions.
- Current SOC: amivantamab and chemo (Papilon).
- Next options: 1L TKI vs TKI and chemotherapy.
- Need to understand patters of resistance.”
Estela (Estelamari) Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 24, 2024, 18:21
Nov 24, 2024, 18:04
Nov 24, 2024, 18:03
Nov 24, 2024, 18:00
Nov 24, 2024, 17:10
Nov 24, 2024, 17:08